PROTAGONIST THERAPEUTICS INC (PTGX)
US74366E1029 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 131.12M | 186.73M | 125.70M | 123.70M | 117.40M | |||
| Marketable Securities | 337.60M | 154.89M | 111.60M | 203.20M | 188.50M | |||
| Receivables | 2.67M | 10.33M | 100.00K | 5.30M | 3.80M | |||
| Other Current Assets | 5.38M | 3.63M | 5.70M | 8.50M | 6.00M | |||
| Total Current Assets | 476.77M | 355.58M | 243.10M | 340.70M | 315.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 12.30M | 2.15M | 4.60M | 6.70M | 6.40M | |||
| Investments And Advances | 114.56M | N/A | N/A | N/A | 2.00M | |||
| Other Non-Current Assets | 225.00K | 225.00K | 200.00K | 200.00K | 500.00K | |||
| Total Non-Current Assets | 127.09M | 2.37M | 4.80M | 7.00M | 8.90M | |||
| TOTAL ASSETS | 603.86M | 357.95M | 247.90M | 347.70M | 324.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 20.66M | 20.40M | 27.10M | 39.50M | 19.90M | |||
| Accounts Payable | 3.05M | 772.00K | 3.60M | 1.60M | 3.10M | |||
| Other Current Liabilities | 20.86M | 102.00K | 500.00K | 2.90M | 17.30M | |||
| Total Current Liabilities | 44.58M | 21.27M | 31.20M | 44.00M | 40.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 27.36M | 0.00 | 1.10M | 3.70M | 4.60M | |||
| Total Non-Current Liabilities | 27.36M | 0.00 | 1.10M | 3.70M | 4.70M | |||
| TOTAL LIABILITIES | 71.94M | 21.27M | 32.30M | 47.70M | 44.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -472.20M | -615.71M | -536.80M | -409.40M | -283.80M | |||
| Additional Paid In Capital | 1.00B | 952.49M | 752.70M | 709.70M | 563.40M | |||
| Common Shares | 1.00K | 1.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 1.34M | -105.00K | -400.00K | -300.00K | 0.00 | |||
| Shares Outstanding | 59.52M | 57.71M | 49.30M | 47.80M | 43.70M | |||
| Tangible Book Value per Share | 8.94 | 5.83 | 4.37 | 6.28 | 6.40 | |||
| Total Shareholders' Equity | 531.91M | 336.68M | 215.60M | 300.00M | 279.60M | |||
| TOTAL LIABILITIES AND EQUITY | 603.86M | 357.95M | 247.90M | 347.70M | 324.50M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 10.70 | 16.71 | 7.79 | 7.74 | 7.85 | |||
| Return On Assets (ROA) | 28.29% | -22.06% | -51.39% | -36.11% | -20.39% | |||
| Return On Equity (ROE) | 32.12% | -23.45% | -59.09% | -41.85% | -23.66% | |||
| Return On Invested Capital (ROIC) | 21.06% | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | 130.08% | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 130.08% | N/A | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21